{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:00:40Z","timestamp":1790992840414,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jad.2021.03.087","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T12:32:54Z","timestamp":1617453174000},"page":"16-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Association between angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and major psychiatric disorders"],"prefix":"10.1016","volume":"289","author":[{"given":"Wei-Syun","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.jad.2021.03.087_bib0001","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jad.2021.03.087_bib0002","first-page":"368","article-title":"Creating and using realworld evidence to answer questions about clinical effectiveness","volume":"22","author":"de Lusignan","year":"2015","journal-title":"J. Innov. Health Inform."},{"issue":"9","key":"10.1016\/j.jad.2021.03.087_bib0003","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1161\/CIRCULATIONAHA.105.594945","article-title":"Design of randomized controlled trials","volume":"115","author":"Stanley","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jad.2021.03.087_bib0004","first-page":"485","article-title":"Evidence-based medicine: four fundamental problems with the randomized clinical trial (RCT) used to document chemical medicine","volume":"21","author":"S\u00f8ren","year":"2009","journal-title":"Int. J. Adolesc. Med. Health"},{"key":"10.1016\/j.jad.2021.03.087_bib0005","unstructured":"2016, ACC\/AHA\/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America."},{"key":"10.1016\/j.jad.2021.03.087_bib0006","author":"Yancy","year":"2020","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.jad.2021.03.087_bib0007","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ehj.2004.06.003","article-title":"Task force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology","volume":"25","author":"L\u00f3pez-Send\u00f3n","year":"2004","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.jad.2021.03.087_bib0008","first-page":"514","article-title":"Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease","volume":"60","author":"Krysiak","year":"2008","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.jad.2021.03.087_bib0009","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11892-009-0081-y","article-title":"Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering","volume":"10","author":"Ismail","year":"2010","journal-title":"Curr. Diab. Rep."},{"issue":"1","key":"10.1016\/j.jad.2021.03.087_bib0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12916-017-0916-3","article-title":"The renin-angiotensin system: a possible new target for depression","volume":"15","author":"Vian","year":"2017","journal-title":"BMC Med."},{"issue":"10","key":"10.1016\/j.jad.2021.03.087_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.13304","article-title":"Association between angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and suicide","volume":"2","author":"Mamdani","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jad.2021.03.087_bib0012","unstructured":"Database NHIR. Taiwan, http:\/\/nhird.nhri.org.tw\/en\/index.html cited in 2015."},{"key":"10.1016\/j.jad.2021.03.087_bib0013","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0895-4356(99)00082-7","article-title":"Cardiovascular drug prescriptions and risk of depression in diabetic patients","volume":"52","author":"Rathmann","year":"1999","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jad.2021.03.087_bib0014","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000444646","article-title":"Angiotensin converting enzyme inhibitors and risk of mood disorders","volume":"85","author":"Williams","year":"2016","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2021.03.087_bib0015","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/HYPERTENSIONAHA.116.08188","article-title":"Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood disorders","volume":"68","author":"Boal","year":"2016","journal-title":"Hypertension"},{"issue":"13","key":"10.1016\/j.jad.2021.03.087_bib0016","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2165\/00003495-200161130-00001","article-title":"Role of ACE inhibitors in patients with diabetes mellitus","volume":"61","author":"Cordonnier","year":"2001","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jad.2021.03.087_bib0017","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10557-006-6570-1","article-title":"The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice","volume":"20","author":"Voors","year":"2006","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.jad.2021.03.087_bib0018","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000011","article-title":"The roles of ACE inhibitors in lower extremity peripheral artery disease","volume":"23","author":"Barrons","year":"2016","journal-title":"Am. J. Ther."},{"issue":"8","key":"10.1016\/j.jad.2021.03.087_bib0019","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/ajhp\/60.8.788","article-title":"Role of angiotensin-converting-enzyme inhibitors in stroke prevention","volume":"60","author":"Fagan","year":"2003","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.jad.2021.03.087_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0025-7125(02)00174-8","article-title":"ACE inhibitors and ARBs in chronic heart failure: the established the expected and the pragmatic","volume":"87","author":"Poole-Wilson","year":"2003","journal-title":"Med. Clin. North Am."},{"issue":"6","key":"10.1016\/j.jad.2021.03.087_bib0021","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1471-4159.2008.05723.x","article-title":"Angiotensin-converting enzyme 2 in the brain: properties and future directions","volume":"107","author":"Xia","year":"2008","journal-title":"J. Neurochem."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721003220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721003220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:56:54Z","timestamp":1759024614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032721003220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":21,"alternative-id":["S0165032721003220"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2021.03.087","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and major psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2021.03.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}